Full-Time
Senior Medical Science Liaison
Gastroenterology
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
€67.5k - €127.8k/yr
Neuss, Germany + 2 more
More locations: Dresden, Germany | Thuringia, Germany
Remote
Field-based role covering Eastern Germany, including Saxony, Saxony-Anhalt, and Thuringia.
Bachelor's, PhD
 Biology & Biotech (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- The role requires a completed degree in medicine, natural sciences, or pharmacy.
- The role requires sufficient scientific experience in a human medical-clinical context.
- The role requires strong project management skills.
- The role requires very good German and English language skills.
- Act as a scientific expert and implement Medical Affairs product plans in the assigned regional medical-scientific area.
- Proactively and reactively exchange medical-scientific information with external medical and research experts, including communicating in-label product data and discussing clinical study programs and scientific information on products and indications in development.
- Communicate the centrally approved Medical Plan to the regional leadership team, coordinate indication-specific topic requests, and organize regional meetings of multiple leadership teams when needed.
- Develop strategic knowledge of therapy pathways, scientific activities, and developments in core indications, and contribute to identifying open core questions, data gaps, and medical needs for patient outcome solutions.
- Proactively support the development and implementation of a medical strategy.
- Support Global Clinical Operations in identifying potential study centers and developing and maintaining strong partnerships with them.
- Support the setup, planning, and execution of interventional and non-interventional drug studies, including selecting study centers and investigators, preparing for and participating in investigator meetings, and presenting study results in partnership with Global Clinical Operations and in close coordination with Medical Project Leads.
- Identify needs for regional and supraregional Medical Education activities and plan and conduct them strategically.
- Participate in scientific discussions with speakers and deliver presentations at the invitation of the scientific advisory board.
- Represent the company with scientific excellence at national and international congresses, investigator meetings, and Medical Education events.
- Participate in and provide organizational support for advisory board meetings.
- Build, expand, and maintain a Key Opinion Leader network, including engagement with professional societies and health-policy organizations.
- Evaluate and prepare current medical-scientific information from the professional literature based on regional and external needs and the CVT strategy.
- A completed doctorate is preferred.
- Experience with analytical reasoning, analytics dashboards, clinical work, coaching, competitive landscape analysis, cross-functional collaboration, data gathering and analysis, medical affairs, medical communications, medical compliance, medical research, stakeholder engagement, strategic thinking, technical credibility, and digital tools is preferred.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
- Tremfya surged 72.5% to $2 billion, proving the immunology replacement strategy works.
- August 21, 2026 TECVAYLI-daratumumab approval and MONARCH QUEST 3 clearance expand pipelines.
What critics are saying
- July 2026 talc settlement needs 95% claimant approval; failure reopens 76,000 claims.
- Stelara biosimilars keep crushing legacy revenue, and replacement drugs must sustain 2027 growth.
- MedTech growth lagged Q2 expectations; Intuitive Surgical and Medtronic intensify hospital-buying competition.
What makes Johnson & Johnson unique
- J&J spans pharmaceuticals, MedTech, and cash-generating scale after Kenvue’s 2023 spinout.
- Tremfya, Darzalex, Carvykti, and Tecvayli offset Stelara’s 55% Q2 decline.
- AAA balance sheet and 64-year dividend streak signal resilience through patent cliffs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.
The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.